Friday, 30 September 2022
08:33 AM (WIB)
Senti BioScience, Inc.
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from a novel and proprietary combinations of DNA sequences, to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.
Senti Bio is applying its gene circuit technologies to develop an internal pipeline of medicines that use off-the-shelf CAR-NK cells with the goal of addressing major challenges for people living with cancer.
Our mission
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.
Founded on Smart Science
Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with what we refer to as “gene circuits.” These gene circuits, which are created from a novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.
Driven by Strong Leadership
Senti Bio is led by seasoned professionals with a passion for building life-changing therapies. Chief Executive Officer and Co-founder, Dr. Tim Lu, is a pioneer in synthetic biology and has co-founded multiple therapeutics platform companies including Synlogic, Tango Therapeutics, Eligo Bioscience, BiomX, and Engine Biosciences. Chief Technology Officer and Co-founder, Dr. Philip Lee, is an entrepreneur and technology platform builder specializing in cellular systems. Chief Financial Officer, Dr. Deborah Knobelman, is a proven life science executive with broad financial experience spanning senior leadership roles in biopharma companies and Wall Street. Chief Medical and Development Officer, Dr. Kanya Rajangam, is an experienced biotechnology executive with an extensive track record of successfully developing products across multiple modalities including allogeneic cell therapies.
Senti Bio is building a synthetic biology platform that could enable it to program next-generation cell and gene therapies with “gene circuits.” Senti Bio’s lead product candidates utilize off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells outfitted with gene circuit technologies in several oncology indications with high unmet needs.
For more details please come visit Senti Bioscience, Inc.
08:33 AM (WIB)
Senti BioScience, Inc.
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from a novel and proprietary combinations of DNA sequences, to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.
Senti Bio is applying its gene circuit technologies to develop an internal pipeline of medicines that use off-the-shelf CAR-NK cells with the goal of addressing major challenges for people living with cancer.
Our mission
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.
Founded on Smart Science
Senti Bio has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with what we refer to as “gene circuits.” These gene circuits, which are created from a novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments.
Driven by Strong Leadership
Senti Bio is led by seasoned professionals with a passion for building life-changing therapies. Chief Executive Officer and Co-founder, Dr. Tim Lu, is a pioneer in synthetic biology and has co-founded multiple therapeutics platform companies including Synlogic, Tango Therapeutics, Eligo Bioscience, BiomX, and Engine Biosciences. Chief Technology Officer and Co-founder, Dr. Philip Lee, is an entrepreneur and technology platform builder specializing in cellular systems. Chief Financial Officer, Dr. Deborah Knobelman, is a proven life science executive with broad financial experience spanning senior leadership roles in biopharma companies and Wall Street. Chief Medical and Development Officer, Dr. Kanya Rajangam, is an experienced biotechnology executive with an extensive track record of successfully developing products across multiple modalities including allogeneic cell therapies.
Senti Bio is building a synthetic biology platform that could enable it to program next-generation cell and gene therapies with “gene circuits.” Senti Bio’s lead product candidates utilize off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells outfitted with gene circuit technologies in several oncology indications with high unmet needs.
For more details please come visit Senti Bioscience, Inc.